Why real-world HCP insight is becoming a commercial advantage

Tern plc

Pharma companies have used healthcare professional personas for years, but many are still built on limited interviews, workshops and internal assumptions. That makes them useful for alignment, but less useful for execution. If personas do not reflect how clinicians actually think, speak and make decisions in practice, they can weaken messaging, waste spend and reduce the impact of evidence.

Traditional approaches tend to capture what healthcare professionals say in a formal research setting. They are less effective at showing what drives behaviour in real clinical environments, where time pressure, patient complexity, reimbursement issues and changing guidance all shape decisions. As a result, a persona can look credible on paper while failing to explain what really affects uptake.

If a company is working from an outdated or simplified view of its audience, it may focus on the wrong barriers, use evidence in the wrong way or miss the language that actually builds confidence.

The value here is not simply richer insight. It is better accuracy. Real-world language can reveal how clinicians frame problems, what concerns they return to, what evidence they trust and what practical issues affect action. That produces a more grounded view of the audience and gives teams a stronger basis for message development.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search